Genmab A/S Sees Unusually High Options Volume (NASDAQ:GMAB)

Genmab A/S Sponsored ADR (NASDAQ:GMAB) saw some unusual options trading activity on Wednesday. Stock traders acquired 41,576 call options on the company. This is an increase of approximately 3,570% compared to the typical volume of 1,133 call options.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Weiss Ratings upgraded shares of Genmab A/S from a “hold (c)” rating to a “hold (c+)” rating in a research report on Tuesday, September 1st. Guggenheim lifted their price target on Genmab A/S from $40.00 to $42.00 and gave the company a “buy” rating in a research note on Friday, August 7th. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price target on shares of Genmab A/S in a report on Monday, September 14th. New Street Research set a $43.00 price target on Genmab A/S in a report on Wednesday, July 22nd. Finally, TD Cowen upgraded Genmab A/S from a “hold” rating to a “buy” rating and increased their price target for the stock from $32.00 to $43.00 in a research report on Wednesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $39.50.

Genmab A/S Price Performance

NASDAQ:GMAB traded up $0.10 during trading hours on Wednesday, reaching $35.67. 5,154,396 shares of the company were exchanged, compared to its average volume of 2,098,102. The company has a current ratio of 2.46, a quick ratio of 2.44 and a debt-to-equity ratio of 0.81. The firm has a market cap of $22.26 billion, a PE ratio of 28.09, a price-to-earnings-growth ratio of 1.93 and a beta of 0.84. Genmab A/S has a twelve month low of $23.62 and a twelve month high of $35.91. The stock’s 50-day moving average is $32.54 and its 200-day moving average is $28.86.

Genmab A/S (NASDAQ:GMAB) last announced its earnings results on Thursday, August 6th. The company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.17. The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.12 billion. Genmab A/S had a net margin of 19.08% and a return on equity of 14.89%. On average, sell-side analysts anticipate that Genmab A/S will post 1.21 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Genmab A/S

Several large investors have recently bought and sold shares of GMAB. Personal CFO Solutions LLC raised its holdings in shares of Genmab A/S by 3.7% during the first quarter. Personal CFO Solutions LLC now owns 10,866 shares of the company’s stock valued at $292,000 after acquiring an additional 386 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of Genmab A/S by 16.4% in the second quarter. GAMMA Investing LLC now owns 3,978 shares of the company’s stock worth $109,000 after acquiring an additional 561 shares during the last quarter. Summitry LLC boosted its stake in shares of Genmab A/S by 5.3% in the first quarter. Summitry LLC now owns 11,170 shares of the company’s stock worth $300,000 after acquiring an additional 567 shares during the last quarter. AdvisorShares Investments LLC increased its position in shares of Genmab A/S by 2.2% during the first quarter. AdvisorShares Investments LLC now owns 30,853 shares of the company’s stock worth $828,000 after purchasing an additional 653 shares in the last quarter. Finally, Parallel Advisors LLC increased its position in shares of Genmab A/S by 15.9% during the first quarter. Parallel Advisors LLC now owns 4,871 shares of the company’s stock worth $131,000 after purchasing an additional 669 shares in the last quarter. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

About Genmab A/S

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including its DuoBody and HexaBody platforms, to create therapies designed to engage the immune system, target disease-related proteins and improve treatment outcomes.

Genmab’s portfolio includes products developed through partnerships as well as internally discovered candidates.